A Comparison Of Vardenafil And Sildenafil: Treatment Satisfaction Among Men With Erectile Dysfunction And Cardiovascular Risk Factors, And Their Partners
|
|
Dr. Eusebio Rubio-Aurioles, Hartmut Porst, Ian Eardley, Dr Irwin Goldstein |
This prospective pooled analysis of two studies (one US and one European/Mexican) was performed to compare treatment satisfaction with vardenafil versus sildenafil, among men with erectile dysfunction (ED) and their partners.
Men aged ?18 years with ED for >6 months according to NIH criteria and risk factors for cardiovascular disease (diabetes mellitus, hypertension and/or hyperlipidaemia) were eligible to participate in the two randomised, double-blind crossover studies. All participants had to be in a stable, heterosexual relationship for more than the last 6 months. After screening, patients were randomised to receive vardenafil 20 mg or sildenafil 100 mg for 4 weeks, followed by 1 week of washout, then 4 weeks’ therapy with the second drug. The Treatment Satisfaction Scale (TSS) was completed by patients and their partners at the end of each treatment period. Results: A total of 1,057 men were randomised to treatment. After 4 weeks’ treatment, vardenafil was shown by LS mean scores to be superior (nominally significant) to sildenafil in 12/19 patient TSS questions (p<0.05; no questions showed significantly greater improvement with sildenafil). A numerical advantage with vardenafil was observed in 6 questions, while a numerical trend in favour of sildenafil was observed in 1 question. Partners’ TSS results showed equal LS mean scores for sexual desire, and a trend in favour of vardenafil in 14/18 questions. Vardenafil was superior to sildenafil (nominally significant) in the 3 questions relating to duration of erection, hardness of erection and sex when you felt like it. Conclusion: The TSS demonstrated superior satisfaction (nominally significant) among men treated with vardenafil versus sildenafil in 12/19 questions, and numerically higher satisfaction with vardenafil in all but one question. Among partners, the LS mean score with vardenafil was numerically higher than that with sildenafil in 17/18 questions.
|
Eusebio Rubio-Aurioles
other talks by the speaker
|

Dr. Eusebio Rubio-Aurioles
|
EUSEBIO RUBIO-AURIOLES, M.D., Ph.D. obtained his M.D. at Universidad La Salle in Mexico City (1978) México D.F., and his Ph.D. in the Program of Human Sexuality at New York University. (1988) He completed the post-doctoral training course in sex therapy at the Department of Psychiatry of the Mount Sinai Hospital of New York City (1983).Since 1984 he is professor at the Departamento de Psiquiatría y Salud Mental de la Facultad de Medicina de la Universidad Nacional Autónoma de México.In 1987 he founded the Asociación Mexicana para la Salud Sexual, A.C. where he is the director. Since 1993 has completed 22 clinical trials for the development of drugs for the treatment of sexual dysfunction in males and females. He has published several articles in national and international journals and books, he was the Editor of the Antología de la Sexualidad Humana published by the Consejo Nacional de Población. From 1995 to 1998 he served as the first president of the Federación Mexicana de Educación Sexual y Sexología, A.C. He is currently the President of the World Association for Sexual Health (formerly World Association for Sexology)
|
Dr Irwin Goldstein
|
Dr Irwin Goldstein is Director of San Diego Sexual Medicine at Alvarado Hospital, the Secretary of the International Society for the Study of Women’s Sexual Health, a former President of the Sexual Medicine Society of North America and a Clinical Professor of Surgery at University of California at San Diego.
Dr Goldstein has been involved with sexual dysfunction research since the late 1970s. His specialties include penile microvascular bypass surgery, surgery for dyspareunia, physiologic investigation of sexual function in men and women, and diagnosis and treatment of sexual dysfunction in men and women.
Dr Goldstein is currently President of The Institute for Sexual Medicine, Inc., a charitable corporation for education and research in the field. He is a board member of the International Society for Sexual Medicine and a member of the International Academy of Sex Research, the American Urological Association, the American Association of Sex Educators, Counselors and Therapists, and the International Society for the Study of Vulvovaginal Disease.
Dr Goldstein is a 2009 winner of the Gold Medal awarded by the World Association for Sexual Health in recognition of his lifetime contributions to the field.
For more information visit: http://www.sandiegosexualmedicine.com
|
|

Navigation
......................................
......................................
......................................
|
Help
......................................
......................................
......................................
|
Audio Visual Archives
......................................
......................................
......................................
|
Useful
......................................
......................................
......................................
|
|
|
|